Sparkling Sciences Attains Dual U.S. INCI Certifications to Propel Global Expansion in Exosome Ingredients Market
Sparkling Sciences Achieves Dual U.S. INCI Certifications
In a noteworthy development, Sparkling Sciences, a subsidiary of TOMO YUME Group, has successfully obtained dual certifications from the U.S. International Nomenclature Cosmetic Ingredient (INCI) system. This remarkable achievement not only highlights Sparkling Sciences' dedication to cutting-edge exosome research but also sets the stage for its ambitious global expansion strategy into high-performance scalp, hair, and skincare markets. The certifications validate Sparkling Sciences' proprietary research and development capabilities, reinforcing their position as leaders in the biotech beauty industry.
The Certifications
The certifications pertain to two innovative ingredients derived from Sparkling Sciences' advanced biotech processes, which utilize clinical-grade purification techniques combined with freeze-drying technology:
1. Human Hair Follicle Dermal Papilla Cell Exosomes (INCI ID 40983): This premium biotechnology ingredient aims to revolutionize scalp care while conditioning hair roots.
2. Organic Rice Bran-Derived Vesicles (INCI ID 40956): A versatile ingredient known for enhancing skin hydration, improving texture, and boosting hair volume. This botanical component has already been integrated into various commercial formulations, demonstrating its practical applicability.
Dr. Fang-Chen Kao, CEO of Sparkling Sciences, expressed that, "The acquisition of U.S. INCI certification marks a pivotal moment in our R&D journey, signaling international recognition of our technical precision. Our Dermal Papilla Cell Exosomes exemplify our strength in developing next-generation scalp solutions. Guided by our philosophy of 'From Science to Beauty and Health,' our goal is to expand applications across both human and animal healthcare sectors."
Expanding Beyond Cosmetics
Notably, Sparkling Sciences is not limiting itself to human cosmetics. The company has begun large-scale production of highly stable freeze-dried exosome powders, targeting the growing pet healthcare market. This strategic move has already garnered significant interest from industry partners, seeking innovative healthcare solutions for pets.
Future Production Capabilities
To meet the increasing global demand for high-quality exosome ingredients, Sparkling Sciences is in the process of developing a state-of-the-art R&D and manufacturing facility, which is anticipated to be completed in 2026. This new facility will operate under stringent Good Tissue Practice (GTP) standards to ensure the traceability and safety of their products. In the subsequent phases, a framework for Good Manufacturing Practice (GMP) will be implemented, significantly enhancing production capacity for their high-purity exosome ingredients. This expansion positions TOMO YUME Group as a frontrunner in the biotech beauty landscape.
Company Overview
Company Name: Sparkling Sciences
Headquarters: Taipei, Taichung, Taiwan
CEO: Dr. Fang-Chen Kao
Business Scope: Focused on research, development, and manufacturing of exosome ingredients, along with planning and sales of skincare and healthcare products.
Affiliated Companies: TOMO YUME Group; ArcBio Co., Ltd. (Tokyo)
Websites:
With these advancements and achievements, Sparkling Sciences is poised to make a significant impact on the global beauty and healthcare markets, leveraging exosome technology to create innovative solutions that enhance health and beauty across a diverse range of applications.
Topics Consumer Products & Retail）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.